PDL-1 Targeting in Resectable Oesophageal Cancer: a Phase II Feasibility Study of Atezolizumab and Chemoradiation

Conditions:   Esophageal Cancer, Stage II;   Esophageal Cancer Stage III
Interventions:   Drug: Atezolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiotherapy 23 x 1.8 Gy
Sponsors:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   UMC Utrecht
Not yet recruiting - verified March 2017

http://ift.tt/2nInde6